COUR Pharmaceuticals is developing therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. This includes a platform of immune-modifying nanoparticles aimed at treating the root cause of immune disease.

COUR Pharmaceuticals

IPhone / Mobile Compatible

Viewport Meta

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

Global Site Tag

Font Awesome

Senior Board & CEO Advisor

George Davis

Business Management

John Puisis

President and Founder

Michael Boyne

VP Finance

Jill Heady

Director of Immunology

Adam Elhofy

Derrick McCarthy

Associate Director, External Manufacturing

Deven Iatarola

Director of Quality Assurance

Frank Fokta

Senior Director, Clinical Operations and Program Development

Greta Wodarcyk

Finance and Administration

Justin Puisis

Simon Greenwood

Chris Dimitropoulos

Benjamin Rovinski, Ph.D.

John J. Puisis

Founder, President and Chief Executive Officer

Daniel Getts

Executive Director

Brian Bock

Jim Herrmann

CFO / COO

Biotechnology Companies With Fewer Than 1000 Employees (Top 10K)

Private Great Lakes Companies (Top 10K)

Biotechnology Companies (Top 10K)

Great Lakes Companies With More Than 10 Employees (Top 10K)

Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois.

Alpha Wave Ventures

Lumira Ventures

Series A - Cour Pharmaceuticals Development

Venture Round - Cour Pharmaceuticals Development

Debt Financing - Cour Pharmaceuticals Development

Seed Round - Cour Pharmaceuticals Development

Skokie

Illinois

United States

North America

Cour Pharmaceuticals Development

The 10 Biggest Rounds Of January: Generate Capital, Recurrent Energy Top First Month Of Year

The Week’s 10 Biggest Funding Rounds: Generate Capital Goes Big Again, Kore.ai Nabs $150M

Cour Raises $105M in Series A Round with Backing From Big Pharma

Cour Pharmaceuticals lands $105 million for next phase of clinical trials

Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity

Cour's nanoparticles shut off autoimmunity with $105M series A

A biodegradable nanoparticle encapsulating gliadin proteins to induce immune tolerance in celiac disease patients.

A biodegradable nanoparticle encapsulating PDC-E2 aimed at addressing the dysregulated immune system in primary biliary cholangitis.

An investigational therapeutic designed to prevent immune-mediated neuromuscular destruction in Myasthenia Gravis patients.

Targets the immunological drivers of Type-1 Diabetes to stop immune-mediated destruction of pancreatic islet cells.

An investigational therapeutic aimed at preventing autoimmune-mediated skin depigmentation in vitiligo.

A nanoparticle encapsulating AAV protein replacement to induce tolerance to gene therapy treatments.

Canada

Pakistan

Asia

India

HTML5

F5 NGINX

GoDaddy Premium DNS

Google Compute Engine

jQuery

Office 365

DigiCert

Marketing Consulting

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Oct 11, 2024 5:13 PM	68d4dcda
public peers	general	Oct 2, 2024 12:09 PM	771874ee
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Oct 10, 2024 11:09 AM	1a5400d5
company summary	general
signals	general	Oct 2, 2024 12:09 PM	1cc26fce
crunchbase trigger	general	Nov 18, 2024 2:12 PM	8f51a08a
crunchbase profile	general	Nov 19, 2024 10:38 AM	5e74cc2d
li profile	general
translate crunchbase fundingrounds	general	Nov 19, 2024 10:56 AM	d8487deb
peers	general	Oct 2, 2024 12:09 PM	82f7169a
news basic	general	Oct 2, 2024 12:09 PM	91c6c291
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:COURPHARMA

COUR Pharmaceuticals